E-portal to track sale of quality medicines created in India

23 March 2017

India’s Union Health Ministry plans to create a digital platform to track and regulate sale of quality drugs in the country, according to a posting on Brand India Pharma*.

The aim of the initiative is to make the entire trade channel transparent. The "track and trace" mechanism which has been in existence to regulate the supply of quality medicines through the net is applicable for people in and outside India.

Bar coding on medicine packs is, however, done only for export consignments currently. The new move is of crucial importance as around 3% of drugs sold in India have been found to be of substandard quality as per a recent survey.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK